» Articles » PMID: 9743610

Recovery from Guillain-Barré Syndrome is Associated with Increased Levels of Neutralizing Autoantibodies to Interferon-gamma

Overview
Date 1998 Sep 23
PMID 9743610
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Guillain-Barré syndrome (GBS) is an immune-mediated demyelinating disease of peripheral nerves that is often preceded by an infection and is usually self-restricted. The Th1 cytokine interferon-gamma (IFN-gamma) is thought to be disease-promoting in organ-specific autoimmune diseases. We report the spontaneous induction of IFN-gamma and a mechanism involving the generation of neutralizing autoantibodies (Aabs) to IFN-gamma that may regulate the disease. Numbers of cells spontaneously secreting IFN-gamma in peripheral blood were augmented in GBS, in particular at the peak of clinical disease, and decreased during recovery. This decrease was associated with elevated serum concentrations of IgG Aabs to IFN-gamma. These Aabs specifically bound to IFN-gamma and neutralized its effects in a biological assay. Aabs to IFN-gamma are proposed to be another important regulatory mechanism in IFN-gamma-driven GBS.

Citing Articles

IL-1RA autoantibodies: insights into mechanisms and associated diseases.

Bouayad A Am J Transl Res. 2024; 16(2):374-386.

PMID: 38463591 PMC: 10918145.


Current Biomarker Strategies in Autoimmune Neuromuscular Diseases.

Oeztuerk M, Henes A, Schroeter C, Nelke C, Quint P, Theissen L Cells. 2023; 12(20).

PMID: 37887300 PMC: 10605022. DOI: 10.3390/cells12202456.


Anti-cytokine autoantibodies: mechanistic insights and disease associations.

Cheng A, Holland S Nat Rev Immunol. 2023; 24(3):161-177.

PMID: 37726402 DOI: 10.1038/s41577-023-00933-2.


A review of the role of genetic factors in Guillain-Barré syndrome.

Safa A, Azimi T, Sayad A, Taheri M, Ghafouri-Fard S J Mol Neurosci. 2020; 71(5):902-920.

PMID: 33029737 DOI: 10.1007/s12031-020-01720-7.


Functional Analysis of Anti-cytokine Autoantibodies Using Flow Cytometry.

Merkel P, Lebo T, Knight V Front Immunol. 2019; 10:1517.

PMID: 31354706 PMC: 6640114. DOI: 10.3389/fimmu.2019.01517.